Background: In the past, treatment results in Indian children with ALL have been poor, primarily due to inadequate chemotherapy and supportive care, but perhaps reflecting differences from Western countries in the pattern of subtypes. In an attempt to improve survival, we have used a more intensive treatment protocol, MCP841, and examined prognostic factors.
Introduction
The intensive chemotherapy protocols used in the last 15 years have improved the outcome of treatment of children with acute lymphoblastic leukemia (ALL) [1] [2] [3] [4] [5] [6] . Unfortunately, similar improvements have been achieved only in the more affluent of the developing nations and only in major centers from these countries [7] [8] [9] [10] . Other countries, such as India, have generally reported low survival rates, largely because of limitations in the existing health care systems such that treatment regimens of sufficient intensity are impractical, but possibly also reflecting differences in the general health (nutritional status, intercurrent infections etc.) of the patients or in the biology of ALL [11] [12] [13] [14] .
The Tata Memorial Hospital in Mumbai (Bombay), India, is a major cancer center to which patients are referred from all over the country, and which trains a large number of oncologists. Each year, approximately 150 children and adolescents with previously untreated ALL are seen. At this center, we have used a single protocol for the treatment of patients with ALL, aged 1-24 years, since June of 1986. This protocol, MCP841, which is more intensive than previous protocols used at the Tata Memorial Hospital, was designed in collaboration with the National Cancer Institute (USA). Our goals were to define the characteristics of ALL in India more precisely, to determine whether a more intensive chemotherapy program than previously used at the Tata Memorial Hospital would give improved results, and to define risk factors in our patient population. This population differs markedly from western populations with respect to the frequency of illiteracy, poverty, malnutrition and chronic infectious diseases. While recognizing that a more intensive protocol could lead to significant toxicity in such a population, particularly in institutions with limited experience in supportive care, we surmised that if MCP841 were significantly more effective its benefits with respect to improved survival rates would outweigh any negative impact of increased Each cycle subsequent to I| began as soon as the neutrophil count was 3= 1000/mm 3 and the platelet count was > 100,000/mm 3 .° Dose for patients ^ 3 years; patients aged two years received 10 mg; patients aged one year received 8 mg; and patients less than one year received 6 mg.
toxicity. An additional component of the present study was, of course, to improve the quality of supportive care to a level commensurate with the increased intensity of protocol MCP841.
In this paper, we report the efficacy and major toxicities of protocol MCP841 and an analysis of prognostic factors in this Indian patient population.
Patients and methods
previously untreated patients) were accepted for treatment on MCP841 to ensure minimal loss to follow up. All patients were offered assistance with travel and local accommodation. No hospitalization charges were made and the cost of drugs was subsidized where necessary. Thus, every effort was made to treat as many eligible patients on the protocol as possible.
The diagnosis of ALL was confirmed by examination of a bone marrow aspirate specimen. Cytochemistry (PAS, Sudan black and myeloperoxidase) was performed on all samples and immunophenotyping was performed in the majority of cases (488 of 530) using a panel of monoclonal antibodies which included CD2, 4, 5, 7, 8, 10, 1 lb, 15, 19, 20, 36, 45, 13, 33 , HLA-DR, surface immunoglobulin (SIg) and an indirect immunofluorescence detection system. Common ALL was defined as CD10 positive, with all T-cell markers negative. T-cell ALL was defined as either CD5 or CD7 positive, with or without additional T-cell makers, but with B cell markers negative. Patients with L3 (French-American-British criteria) morphology and/or B-ALL (SIg positive) were excluded from the study. A complete history and physical examination, biochemical profile, chest X-ray, complete blood count and cerebrospinal fluid (CSF) examination were performed in all patients. Informed consent was obtained from all patients or parents of minor children prior to protocol entry.
Risk criteria and definitions
Because of a lack of information regarding risk factors in Indian patients with ALL, we decided to include only two risk categories for the purpose of determining therapy. 'Low-risk' patients were to be defined as those with white blood cell counts (WBC) of 10,000 per mm 3 or less, age between three and six years; absence of significant lymphadenopathy; a mediastinal mass or hepatosplenomegaly; a normal CSF and absence of cranial nerve palsies. All remaining patients were to be assigned to the 'high-risk' category. However, because so few patients fell into the low risk category, (only seven patients (1.3%) met the definition of 'low risk' and none were seen in the first four years of the study) it was decided to treat all patients on the high-risk arm.
For purposes of analysis, any patient with one or more palpable lymph nodes of > 1 cm in size was considered to have lymphadenopathy. Most patients (405) had two or more palpable lymph nodes and only 12, a single enlarged lymph node, (11 were between 1 and 3 cm, and 1 was 3-5 cm in diameter). A total of 345 patients had three or more 1 -3 cm lymph nodes or one or more lymph nodes greater than 3 cm in diameter. In the present analysis, patients with lymphadenopathy were not subdivided.
Hepatomegaly and splenomegaly were defined clinically, i.e., the liver or spleen was palpable. The term hepatosplenomegaly includes either hepatomegaly or splenomegaly, or both. Most patients (318) had both.
Specific therapy
Protocol MCP841 (high risk arm) is outlined in Table i . Patients received two induction cycles (I| and I2), repeat induction (RIO, consolidation (C) and six maintenance cycles (M). Central nervous system (CNS) prophylactic therapy included cranial irradiation (2000 CGy) for children above the age of two years. Patients less than two years were treated with an alternative CNS prophylactic regimen containing high dose cytarabine. All patients received 12 weekly intrathecal injections of methotrexate during the induction and consolidation phases of therapy. The total duration of therapy was approximately two years.
All previously untreated patients with ALL aged less than 25 years seen at the Tata Memorial Hospital after June 1986 were considered for treatment on protocol MCP841. In view of the fact that patients come to the Tata Memorial Hospital from all over India, only patients willing to remain in Mumbai for four months for the induction-consolidation regimen and to return for follow up visits (approximately two thirds of
Supportive care
All patients were hospitalized for the initiation of induction therapy. Patients with WBC over 100,000 per mm 3 were treated with low dose prednisone, 10 mg/m 2 every 12 hours for two doses, prior to commencing the induction cycle, and urine output and electrolytes were . Our policy with respect to the antibiotic treatment of febrile neutropenic patients evolved during the study period. Initially carbenicillin/gentamycin was used. Subsequent antibiotic combinations included cephelaxin/gentamycin and cefotaxime/amikacin. Since December 1989, however, at which time an analysis of the pattern of infection and sensitivity of organisms previously identified was completed, all febrile neutropenic patients have been initially treated with ceftazidime plus amikacin, followed by the addition of an antifungal agent when fever persisted for more than 72-96 hours. Pneumocystis carinii prophylaxis with sulfamethoxazole and trimethoprim was administered throughout therapy. Oral dotrimazole was given during induction-consolidation cycles as prophylaxis against fungal infections. Blood transfusions were given if hemoglobin levels (Hb) were below 10 gm/dl during treatment and platelet transfusions were given when the platelet count was below 20,000 per mm 3 or in the presence of bleeding.
Since 1989, only disposable needles and syringes have been used for venous access. The hospitalization time was also minimized as far as possible. All patients and parents were educated with respect to hygiene, care of indwelling lines, taking temperatures, and procedures to follow in the event of fever.
Evaluation of response
A bone marrow examination was performed at the end of the first induction cycle. A complete remission (CR) was defined as less than 5% blasts in a normocellular marrow aspirate and the absence of clinical evidence of disease. Patients with more than 5% blasts in the bone marrow at this time were defined as non-responders (NR). Patients whose bone marrow could not be assessed due to early mortality were considered not evaluable (NE) for response, and were considered as induction deaths. Relapse was defined as the presence of unequivocal malignant blast cells (> 25%) in the bone marrow or of histologically or cytologically documented extramedullary leukemia after the achievement of CR.
Statistical methods
The overall survival (OS), event free survival (EFS), and disease free survival rates (DFS) were calculated using the Kaplan-Meier method [15] . OS was calculated from the date of commencement of treatment to the date of last follow-up. EFS was calculated from the date of commencement of treatment to the date of last follow up or an event (early death, induction failure, relapse or death during remission). DFS was calculated for CR patients from the date of commencement of treatment to the date of relapse or the date the patient was last known to be in complete remission. For the analysis of DFS, patients who died from causes other than relapse were censored at the time of death. For the analysis of factors associated with toxic deaths, patients known to be in remission when last seen, but who subsequently died, and in whom the cause of death was unknown, were censored (11 of 49 remission deaths).
Patient characteristics were analyzed with respect to their influence on prognosis using the log rank statistics and trend test for univariate analysis, and the Cox proportional hazard regression model for multivariate analysis [16] , WBC, blast count, platelet count and LDH level were logarithmically transformed before analysis and treated as continuous variables unless otherwise stated. Associations among patient characteristics were examined using the Spearman rank correlation method, Wilcoxon rank sum test, Fisher's exact test and Fisher-Freeman-Halton test. Height for age and weight for age were based on published tabulations for affluent Indian children [17, 18] . In this analysis, patients were grouped only as either above or below the median value for age.
Results
A total of 530 patients were accrued on study from June 1986 through December 1993. The patient characteristics are shown in Table 2 . Most of the patients had hepatosplenomegaly (80%) or lymphadenopathy (78.7%) or both. Only seven (1.3%) had CNS disease. Sixty-nine percent of patients had common ALL and 21% had T-cell ALL. Patients with common ALL were significantly (P < 0.00001) younger (median age six years) than patients with T cell ALL (median age, 12 years). Patients with T-cell ALL also had significantly higher Hb (P = 0.0003), higher WBC (P < 0.00001), more lymphadenopathy (P = 0.0002) and were much more likely to have a mediastinal mass (P < 0.00001) than other patients. Patients with a mediastinal mass, being predominantly of T-cell type (33 of 41), also, as a group, had higher Hb (P < 0.0001), higher WBC (P = 0.0004) and older age (P = 0.0013) than other patients. In common ALL patients, lymphadenopathy was significantly more frequent in patients less than 10 years of age (83%, versus 64% for patients 10 years or above, P = 0.0002). Among the 530 patients, 484 (91.3%) achieved a CR by the end of the lj regimen and 10 patients failed to respond. Thirty-six patients died during the I] cycle, all except one being known to be toxic deaths (infection 26, hemorrhage seven, toxicity other than infection or hemorrhage two, and cause of death not reported one). The early mortality rate was significantly higher (P = 0.014) before 1990 (21 of 205; 10.2%) compared to 1990 and subsequently (15 of 325; 4.6%). Interestingly, toxic deaths in remission (11 patients in whom the cause of death is unknown were excluded from this analysis) occurred significantly more frequently (P = 0.003 using the Bonferroni correction for the choice of an optimal cutoff) prior to 1988 (12 of 64, 19%) than subsequently (26 of 455,6%). Events by period of accrual are shown in Table 3 . For the entire series, the OS, DFS and EFS (Figure 1 ) at five years were 53%, 60% and 49%, respectively.
Prognostic factors
Univariate analysis Several of the prognostic factors examined by univariate analysis were significantly associated with EFS. An advantage was observed for patients with lower WBC and higher Hb or platelet count, the risk of an event increasing as the value of the WBC increased, or the platelet count or Hb decreased. Other factors associated with improved EFS included serum LDH less than 500 IU, year of accrual 1990 or later (although most of this effect appeared to be due to a particularly high EFS rate for patients accrued in 1990), lack of hepatosplenomegaly, lack of lymphadenopathy, or having a height for age or weight for age above the median. Patients who were above the median for both height for age and weight for age had a significantly better EFS (P = 0.011). Age, sex, phenotype and mediastinal mass did not have a significant impact on EFS.
When the data were analyzed separately for patients with common ALL or T-cell ALL, differences in the effect of various potential prognostic factors on survival were observed. For example, WBC, platelet count and LDH were prognostically significant only in common ALL, but higher Hb and older age were associated with a significantly better prognosis only in T-cell ALL. These findings are summarized in Tables 4 and 5 .
Patients treated since January 1990. Of additional interest were the findings of a subset analysis of the 325 patients treated since January 1990, when an improved antibiotic regimen was introduced for febrile neutropenic patients. Among these patients, the most significant risk factors for EFS were WBC, Hb and lymphadenopathy. The latter two factors also varied in importance according to the WBC. The WBC cutoff that produced the most significant difference in EFS was 60,000 per mm 3 (50,000 per mm 3 gave very similar results). Using the derived value, we observed that for the 80 patients with a WBC of 60,000 per mm 3 or above, the most significant risk factor was the Hb (6 gms/dl or above versus less than 6 gms/dl). For the 245 patients with a WBC of less than 60,000 per mm 3 , the most significant risk factor was the presence of lymphadenopathy. Patients with a high WBC and high Hb had a similar EFS at five years (48%) to those with a low WBC and lymphadenopathy (53%), such that these groups could be combined as an intermediate risk group. Patients with a high WBC and low Hb had a significantly worse EFS (16%) than the intermediate risk group (relative risk 3.2, P = 0.0005) while patients with a low WBC and no lymphadenopathy had a significantly better EFS (77%) than the intermediate risk group (relative risk 0.4, P -0.0007). These data are summarized in Table 6 and Figure 2 . The difference between this group and the two intermediate risk groups (WBC > 60,000 with hemoglobin ^ 6 g/dl and WBC < 60,000 with lymphadenopathy) combined was statistically significant (P = 0.0005). b There was no statistical difference between these two groups. c The difference between this group and the two intermediate risk groups combined was statistically significant (P = 0.0007). Figure 2 . Comparison of EFS among patients enrolledin 1990-1993 stratified according to WBC: WBC < 60,000 with or without lymphadenopathy; and WBC > 60,000 with Hb 5= 6.0 or Hb < 6.0.
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Toxic deaths versus progressive disease.
Patients who died from toxicity were considered separately from those who died from progressive disease.
The most important risk factor for toxic death was the year of entry on study. The toxic death rate was much lower for the period 1990-1993 than for the period 1986-1989 (estimated relative risk 0.49, P = 0.0021). In the earlier period, no other factors were associated with toxic death, whereas in the later period, a low Hb and the presence of lymphadenopathy were significantly associated with the risk of dying from toxicity (P = 0.0011 and P = 0.028, respectively). Height for age and weight for age were not significantly associated with Hb, but patients below the median for each had a greater risk of dying from toxicity (P = 0.049 for height for age and P = 0.023 for weight for age). Such patients also had an approximately 2.6-fold greater risk of dying from toxicity than from progressive disease.
The only significant risk factor for dying from progressive disease in the entire patient group was the WBC (P < 0.0001). For the three WBC groups defined in Table 2 , the estimated five-year survival rates were 72% for those with the lowest WBC ( < 10,000 per mm 3 ), 63% for those with intermediate WBC counts (10,000-50,000 per mm 3 ), and 52% for those with the highest WBC ( > 50,000 per mm 3 ). Within the lowest WBC group, a common ALL phenotype was associated with an improved survival (P = 0.001), while the trend towards poorer survival as WBC increased was also significant (P = 0.0041). In the subgroup of patients with T-cell or null-cell ALL increasing Hb was associated with a lower death rate from progressive disease (P = 0.027 and P = 0.0045, respectively), and also with longer EFS (P = 0.038 and P = 0.0064, respectively).
Multivariate analysis
When all the factors included in the univariate analysis were entered into a multivariate model, only WBC, Hb and lymphadenopathy remained significantly associated with EFS (P < 0.01), indicating that several of the factors included in the model were correlated (Table 4) . LDH when used as a categorical variable was also significantly associated with EFS, but was available only in 456 patients. Hepatosplenomegaly was associated with lymphadenopathy (56% of patients without lymphadenopathy had hepatosplenomegaly versus 87% of those with lymphadenopathy; P < 0.00001), while platelet counts and LDH levels were associated with WBC (Spearman rank correlation coefficients 0.28 and 0.49 respectively; P < 0.00001 for each).
When multivariate models for common ALL and T-cell ALL were examined separately, WBC count, hepatosplenomegaly, blast count and LDH were significant risk factors for common ALL, but after adjusting for age as a risk factor in the T-cell patients, none of the other variables remained significant.
Analysis by standard age and WBC criteria in patients with common ALL
In 1993, a workshop sponsored by the National Cancer Institute of the USA and reported by Smith et al. [19] recommended the use of a uniform approach to risk categorization in common ALL using WBC and age as the basic criteria. The results of this workshop were based on data submitted by institutions and cooperative groups in the USA. Standard risk patients were defined as having a WBC of < 50,000 per mm 3 and age of 1-9.99 years, while high risk patients were defined as having a WBC > 50,000 per mm 3 or age ^ 10 years. For purposes of comparison, we performed a similar analysis on our patients with common ALL (using, as did Smith et al., EFS at four years as the end point), including either all such patients, or patients entered on study only after 1990. Although not stated by Smith et al., US cooperative group protocols accrue patients up to the age of 21 years, so for uniformity we have excluded patients above this age (eight patients) in our own analysis.
We found (Table 7) no significant difference between standard and high risk categories defined in this way in the entire group of common ALL patients and a marginally significant difference (P = 0.036 by the likelihood Table 7 . Event-free survival at four years in common ALL patients < 21 years of age using uniform age and WBC criteria adopted at the National Cancer Institute Workshop.
Risk group Definition
Event-free survival (number of patients) ratio of the Cox model) for the smaller group of patients treated since 1990. WBC remained a significant risk factor when entered into the model as a continuous variable within each of these defined risk groups (P = 0.0003 in the standard risk group and P = 0.03 in the high-risk group for all patients, and P = 0.039 and P = 0.030, respectively in the post 1990 group). Lymphadenopathy significantly influenced EFS only in the high-risk group (P = 0.74 and P -0.0081, for standard and highrisk groups respectively in the larger subpopulation, and P = 0.48 and P -0.023 in the post 1990 subgroup). At first sight, this latter result appears to differ from the results of the analysis shown in Table 6 and Figure 2 , in which lymphadenopathy separated risk groups within the low WBC category. The latter analysis includes all immunophenotypes, but further analysis demonstrated that the apparent discrepancy did not derive from inclusion of T-cell patients -the effect of lymphadenopathy was not significantly weaker in common ALL patients alone or in common ALL patients entered post 1990. However, it is important to note that our low risk group, defined on the basis of WBC alone in Table 6 and Figure 2 , includes patients of >10 years who are included in the high-risk subgroup of Smith et al. It is in this subgroup (low WBC and age of > 10 years) that lymphadenopathy exerts its greatest prognostic significance (relative risk 3.5, compared to less than 1.5 in the remaining groups). The inclusion of these patients in our low-risk group but in the Smith et al. high-risk group accounts for the bulk of the apparent discrepancy. Hb was not a significant prognostic factor in any of the four subgroups.
As expected, no significant differences were observed in T-cell patients divided into standard and high-risk groups according to the Smith et al. criteria.
Recurrent disease
To date, 145 of the 484 patients (29.9%) who achieved CR have relapsed. The bone marrow was the most frequent site of relapse, occurring as the sole site of relapse in the majority of patients (106 patients). Iso-lated CNS and testicular relapse were observed in 11 and 12 patients respectively. Five patients had combined bone marrow and CNS relapse and 10 patients had combined bone marrow and testicular relapse. One patient had a relapse in the mediastinum. Most patients relapsed while receiving chemotherapy or within six months of the end of therapy (106 of 145,73.1%)
Toxicity
The major toxicities observed were myelosuppression and infection during the induction -consolidation phases of therapy. During cycle I 1; for which data was collected for the majority of patients, grade 4 neutropenia was observed in 88.5% of cycles, febrile neutropenic episodes were documented in 84.9% of cycles and infection was documented in 52.6% of these episodes. Overall, 50 patients died from bacterial and fungal infections, and 10 from hepatitis B infection during induction or while in remission.
Other major organ toxicities observed included severe hepatotoxicity in 11.7% of patients and altered renal function in 4.7% of patients. Seizures occurred in 24 patients (4.5%). No etiology could be determined in 13 of these patients, but in seven the cause was attributed to cerebral infarctions or bleeding, and in four, to infection. Severe peripheral neuropathy (paralysis without recovery of motor function) occurred in four patients. An additional six patients experienced profound sensory or motor deficits that interfered with function, but resolved over time. Paraplegia, attributed to intrathecal methotrexate, was observed in two patients. Six patients developed pancreatitis, and one of these died as a result of this complication.
Discussion
In general, the prognosis of childhood ALL in the developing world remains poor due to a multitude of adverse clinical and social factors, the most prominent among these being the lack of resources available to both patients and health care professionals [20] . This often leads to delay in diagnosis, which may influence tumor burden and treatment outcome. The impact of delayed diagnosis on outcome (as well as on the clinical presentation) is, however, difficult to quantify. In addition, differences in the environment and lifestyle as well as potential genetic differences, may influence not only the incidence of ALL, which appears to be some threefold lower in India than in the USA [21] , but also its biology; T-cell ALL, for example, is more frequent in India (perhaps because of a paucity of precursor B-cell ALL) [22] [23] [24] . Differences in biology could influence disease extent as well as the results of therapy. Similarly, environmental factors may influence the toxicity of therapy because of affects on drug metabolism and excretion. Nutritional factors and prevalent infectious diseases are likely to be among the most important environmental factors in these respects [25] [26] [27] [28] . Thus, in order to improve the survival of patients with ALL in developing countries, it is important to conduct research into the biology, response to treatment and prognostic factors in the developing countries themselves. Effective protocols from the western world, although constituting a starting point, may, for a variety of reasons, not prove to be optimal, or factors used to assign patients to different risk groups may differ in developing countries.
In the present series, patients with ALL in a single Indian institution were treated uniformly with a standard protocol in order to identify problems and risk factors that might be specific to this patient population. The protocol included a reinduction cycle as has been shown (subsequent to the design of the protocol) to be important in recent studies in Europe and the United States, even for low-risk patients [4, 29] . In the group of 530 assessable children and adolescents enrolled on MCP841 since 1986 the CR and five-year EFS rates of 91.3% and 49%, respectively, represented a significant improvement over past protocols used in this institution [11, 12] . The results are similar to those reported from Egypt [30] and Madras (India) [31] , with the same protocol, and also, to results obtained in Pakistan between 1990-1993 using a modified BFM protocol [32] . The results appear, however, to be inferior to those reported from Europe, the USA, and from some centers in the more economically advanced developing countries [4-10, 33, 34] . There are a number of possible explanations for this, including a higher rate of toxic deaths in Indian patients (which in turn may relate to poorer nutritional status or underlying infections), more extensive disease at presentation, differences in the biology of ALL in India, or a combination of these. It is also possible that the treatment regimen is still not intensive enough, or lacks important drugs (for example, systemic methotrexate was not included).
There is no question that the toxic death rate was high in this population -36 patients died during induction, and 49 died while in remission -a total of 16.9% of patients. This is higher than in series reported from Europe and the USA, and accounts for most of the difference in EFS. The toxic death rate decreased in the period 1990-1993 compared to 1986-1989 as supportive care improved, with a resultant improvement in EFS, such that this problem has been partly overcome. Given the high rate of toxic deaths, it seems likely that a more intensive protocol than MCP841, at least during the initial period of this study, would have produced an unacceptably high toxic death rate. The possibility that a fraction of the patients who died during induction may have been sufficiently debilitated at the time of presentation that they would have died even with the level of supportive care that can be delivered in industrial nations should also be considered; indeed, low Hb and lymphadenopathy were associated with an added risk for toxic death in patients treated since 1990, and both of these factors are more frequently present in Indian patients. If this is the case, high toxic death rates may persist in Indian series for the foreseeable future, irrespective of continued improvements in supportive care. Nutritional status could be relevant to toxic death, and there was some evidence that height for age and weight for age had a greater impact on toxic death than on disease progression. A more detailed analysis of the possible associations among these and other factors, and their influence on outcome is planned.
Our analysis suggests that this Indian patient population differed significantly from western ALL patient populations with respect to potential prognostic factors. Although the fraction with a WBC above 50,000 per mm 3 did not differ greatly from western series, a much higher proportion had lymphadenopathy, and hepatomegaly or splenomegaly, suggesting that Indian patients have significantly higher burdens of leukemia cells at presentation. However, the issue may not be as simple as this. In the multivariate analysis of prognostic factors, WBC, lymphadenopathy, Hb and LDH (when used as a categorical variable) were significant risk factors. The significance of WBC, lymphadenopathy and Hb remained when each was adjusted for the other two significant factors, suggesting that these are independent variables and therefore cannot simply be alternative correlates of tumor burden. In contrast, LDH, and platelet count were associated with WBC, whereas organomegaly was associated with lymphadenopathy, indicating that bulky systemic disease and high WBC have separate associations as well as separate impacts upon survival. This could reflect differences in the biology of the neoplastic cells associated with these clinical characteristics.
Interestingly, only a little more than half of the small fraction of patients without lymphadenopathy had hepatosplenomegaly, while almost 90% of those with lymphadenopathy had hepatosplenomegaly. Lymphadenopathy is much less prominent in western patients, and is, therefore, rarely examined as a prognostic factor; hepatosplenomegaly, but not lymphadenopathy, for example, has for long been included in the definition of risk groups for BFM protocols [4] . Lymphadenopathy occurs more frequently in patients with T-cell ALL and in such patients has been reported to be of prognostic significance in univariate but not multivariate analyses [35] . In the present series, almost 80% of patients had lymphadenopathy, and it appeared to be of greater significance to outcome than hepatosplenomegaly. In the few patients (52) with common ALL who did not have lymphadenopathy, EFS was 73% at four years. While lymphadenopathy is more common in patients with T-cell ALL in western series, in the present series, the majority of patients with common ALL as well as those with T-cell ALL had marked lymphadenopathy, and in patients with common ALL, lymphadenopathy was even more frequent in children less than 10 years of age than above this age. To determine whether lymphadenopathy is a marker of biological subtype, results from delay in diagnosis, or pertains to other genetic or environmental differences in Indian patients, will require further investigation.
Similarly, the prognostic importance of Hb appears to be greater in the present series than in most western series, and, strikingly, differs from western series in that in the latter, higher Hb is associated with a worse prognosis and has been used as a marker of a poor prognostic group [35] [36] [37] , whereas in our series a lower Hb was associated with a worse prognosis. Patients with a T-cell immunophenotype in the USA and Europe have been shown to have higher Hb than other patients [4, 35] , as was the case in our series. Hb in Indian children did not appear to be a measure of undernourishment, since it did not correlate with either height for age or weight for age. Interestingly, in contrast to other published data regarding very high risk patients, CNS involvement at presentation was not frequent in our series, while the rate of CNS relapse was quite low (3.3%).
Another striking difference in our series, compared to others, was that the prognostic importance of WBC count was observed only in common ALL, but not in T-cell ALL. Mediastinal mass was a favorable prognostic factor in a recent series of patients with bulky extramedullary disease [36] , although in our series this was not so. The explanations for these differences are unclear. Surprisingly, age was not a significant prognostic factor overall, or in common ALL, although in univariate analyses age reached significance in T-cell ALL, with older patients having a better outcome. In some series of T-cell ALL patients, younger patients tend to do better [35] , but age was not a significant prognostic factor in a recent large study conducted by the Children's Cancer Group in which high-risk patients, the majority with T-cell disease, were randomized to one of four different regimens [36] . Interestingly, in the present series, after adjusting for age in the T-cell subset, none of the other potential prognostic factors tested reached statistical significance.
In order to facilitate comparison of the present series with other published series, we have also analyzed our data according to the basic risk factors of age and WBC suggested by Smith et al. for precursor B-cell patients [19] . We found only a marginally significant difference between standard and high risk patients with common ALL treated from 1990 onward, defined according to the criteria used in this publication. WBC (as a continuous variable) and lymphadenopathy were able to further define risk within the standard and high risk patient groups.
The differences in our series compared to western series with respect to the relative importance of factors normally considered to be surrogate markers of tumor burden or of tumor biology is of relevance to the stratification of Indian patients into treatment groups. WBC and age would appear to be insufficient to accurately define risk. Differences in the relative importance of prognostic factors compared to western countries, have also been reported from other developing countries, although some of these differences could be artifactual, resulting from the confounding factor of high toxic death rates. In our series, for example, although toxic deaths were decreased after the first few years of the study, the relapse rate remained essentially constant throughout. Moreover, lower Hb and the presence of lymphadenopathy were associated with a higher rate of toxic deaths in the later period. These associations may have been obscured by the relatively less effective supportive care in the earlier period. Differences in the relative importance of prognostic factors could reflect differences in the frequency of various molecular genetic abnormalities which may influence therapy outcome independently of tumor burden [38, 39] . In Africa, race has been shown to influence outcome independently of the standard prognostic factors, clearly indicating that the latter may not be sufficient to identify risk groups in all patient populations [13, 14] . We have recently provided preliminary evidence that the TEL/AML1 translocation, which is present in 25% of patients from western nations, and has been associated with improved outcome, occurs less frequently in Indian patients [40] .
Of course, treatment itself is the most important determinant of outcome. In the present protocol, in contrast to BFM and some other protocols, high-dose methotrexate was not used because of expense and lack of experience with the management of high-dose methotrexate infusions in India. The potential influence of this, or of other therapy elements on the EFS of Indian patients is a matter for speculation, but it is interesting that excellent results were recently reported in high-risk patients with a slow response to therapy without using high-dose methotrexate [41] .
Our experience, similar to that of others [42] , has demonstrated that improved results can be obtained, at least in some major centers in developing countries, with the use of more intensive therapy, although maximal benefit will only be achieved when supportive care is also improved. In addition, such results may not yet be translatable to entire countries or regions [43] . While our results still appear to be inferior to the best reported results, this may reflect the high-risk patient population, higher toxic death rates, and possibly differences in the biology of the disease rather than, or in addition to the treatment itself. Overall, our results confirm the need to redefine risk factors separately for ALL patients in different world regions.
